New nasal spray aims to zap migraines fast
NCT ID NCT07304518
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests whether a single dose of PRT-064040 nasal spray can quickly relieve moderate to severe migraine pain and the most bothersome symptoms. About 456 adults with a history of migraines will receive either the spray or a placebo. The main goal is to see if more people are pain-free and symptom-free two hours after using the spray.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PRT-064040 nasal spray
What this could lead to
If it works, this could provide a fast-acting, non-pill option to stop migraine pain and bothersome symptoms within hours.
What could go wrong
This is an early Phase 2 trial with 456 people, so results may not apply to everyone. The spray might not work better than placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Medical Center of PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, 100039, China
Contact Phone: •••-•••-•••• Email: •••••@•••••